.webp)
Facial aesthetics is moving beyond volume correction alone.
Today, treatment planning increasingly considers several factors together — facial structure, skin quality, tissue support, and how an injectable treatment may contribute to longer-term aesthetic outcomes.
This shift has brought growing attention to hybrid biostimulation, an approach that combines structural correction with biostimulatory activity within a more comprehensive facial treatment strategy.
But how does this approach work in practice? What clinical evidence supports this approach? And where does Genefill DX fit into the evolving landscape of facial aesthetics?
These questions will be explored in the next episode of The Aesthetic EDGE, presented by BioScience in collaboration with IMCAS Academy.
The live aesthetic medicine webinar brings together four expert perspectives to explore the science of skin quality, clinical evidence for hybrid biostimulation and combination treatment protocols across facial and body aesthetics.
What Is Hybrid Biostimulation in Facial Aesthetics?
For many years, injectable treatments have primarily been discussed according to what they correct — volume loss, facial contours, wrinkles or specific aesthetic concerns.
Hybrid biostimulation introduces a broader perspective.
Rather than looking only at immediate structural correction, this approach considers how volume, facial definition and tissue quality can form part of the same treatment strategy.
This is increasingly relevant as aesthetic practitioners look for approaches that support natural-looking facial results while taking the quality and characteristics of the surrounding tissue into consideration.
In practice, this means treatment planning may involve more than simply deciding how much volume is required. Facial anatomy, skin quality, treatment area, patient objectives, and the mechanism of the injectable itself can all influence clinical decision-making.
Episode 3 of The Aesthetic EDGE explores this evolving approach in greater depth, beginning with the science of skin quality before moving into the clinical evidence behind Genefill DX and hybrid facial biostimulation.
Why Skin Quality Matters in Modern Facial Aesthetics
Facial ageing is not defined by volume loss alone. Changes in hydration, texture, firmness and overall tissue quality can influence how the face looks and how aesthetic treatments should be planned.
This is one reason why skin quality treatments and biostimulatory approaches have become increasingly relevant within modern aesthetic medicine.
During her session on The Science of Skin Quality & Hybrid Biostimulation, Dr. Gabriela Casabona will examine the scientific principles behind skin quality and explore how hybrid approaches can be considered within contemporary facial treatment strategies.
Understanding these principles is important because achieving an aesthetic result is not simply about correcting one isolated feature. It requires looking at the face more comprehensively and considering the relationship between structure, proportion, and tissue quality.
Genefill DX: A Hybrid Approach to Facial Biostimulation
At the centre of the facial aesthetics discussion in Episode 3 is Genefill DX.
Genefill DX combines hyaluronic acid and dextranomer within a hybrid formulation developed for facial aesthetic applications.
Hyaluronic acid contributes to structural correction and volume, while the dextranomer component introduces a biostimulatory dimension to the treatment approach.
This combination makes Genefill DX particularly relevant to the wider discussion around dermal fillers and facial biostimulation, where the objective is no longer limited to restoring volume alone.
Instead, practitioners can consider how an injectable fits into a broader treatment strategy that takes facial definition, structural support and tissue quality into account.
From Science to Clinical Evidence with Genefill DX
Understanding the concept of hybrid biostimulation is one part of the discussion. Examining the clinical evidence behind a hybrid injectable is equally important.
During his session — Genefill DX: Clinical Evidence for Hybrid Biostimulation, Dr. Luis Mastronardi will take a closer look at Genefill DX and the clinical perspective supporting its use within facial aesthetics.
The session will connect the scientific principles of this treatment concept with their practical relevance for aesthetic practitioners, providing a more evidence-led perspective on how this approach can be incorporated into treatment planning.
For doctors interested in Genefill DX, facial fillers, hybrid biostimulation, regenerative aesthetics, and evidence-based aesthetic medicine, the session offers an opportunity to explore the topic beyond theory.
What Makes Hybrid Facial Treatment Planning Different?
Hybrid treatment planning is not simply about combining different mechanisms in one product or using several treatments at the same time. It starts with understanding what the patient actually needs.
Facial proportions, anatomy, skin quality, tissue characteristics, and aesthetic objectives can all influence the treatment approach.
A patient requiring structural definition may present very differently from someone whose primary concern is related to skin quality or age-related tissue changes.
This is why modern facial aesthetics increasingly relies on individualised treatment planning rather than universal protocols. The goal is to understand what each treatment can contribute and how it fits into a wider aesthetic strategy.
For practitioners, this makes knowledge of product characteristics, clinical evidence, and patient selection particularly important when working with hybrid fillers and biostimulatory treatments.
Beyond the Face: Understanding Combination Protocols
While Genefill DX brings the webinar's hybrid biostimulation discussion into facial aesthetics, Episode 3 of The Aesthetic EDGE also looks beyond the face.
Body contouring has different anatomical, mechanical, and aesthetic requirements, making treatment planning and product selection equally important.
During her session on Advanced Body Contouring: Combination Protocols with HYAcorp, Dr. Patricia Oliveira will explore how HYAcorp hyaluronic acid body fillers can be considered alongside biostimulatory approaches within advanced body-contouring strategies.
Including both facial and body applications in one webinar highlights an important principle in modern aesthetic medicine: different anatomical areas require different treatment strategies, but evidence-led planning remains fundamental across both.
Why Clinical Evidence Matters in Aesthetic Medicine
Innovation in aesthetic medicine continues to introduce new products, mechanisms, and treatment approaches — but innovation alone is not enough.
Understanding the evidence behind a product or technique is an important part of responsible clinical decision-making.
Clinical evidence can help practitioners better understand treatment behaviour, patient selection, expected outcomes, and how an injectable may fit within an individualised treatment plan.
This is particularly relevant for emerging areas such as hybrid biostimulation, where structural correction and biostimulatory activity are being considered together.
By dedicating an entire session to the clinical evidence behind Genefill DX, Episode 3 aims to move the discussion beyond terminology and into its practical application in facial aesthetics.
The Aesthetic EDGE: Expert Education in Aesthetic Medicine
The Aesthetic EDGE — Education, Development, Growth and Expertise — is an educational webinar series from BioScience in collaboration with IMCAS Academy.
The series brings together international experts to explore evolving topics in aesthetic medicine through scientific discussion, clinical experience, and practical treatment considerations.
From anatomy and injection techniques to biostimulation and combination protocols, each episode is designed to support continued aesthetic medicine education for healthcare professionals.
Episode 3 continues this approach by exploring hybrid biostimulation from its scientific foundations through to clinical evidence and treatment strategies across both the face and body.
Previous episodes of The Aesthetic EDGE are also available through the BioScience Digital Academy.
Who Should Attend This Hybrid Biostimulation Webinar?
Episode 3 is particularly relevant for healthcare professionals interested in:
- Genefill DX
- Hybrid biostimulation
- Facial biostimulation
- Hybrid dermal fillers
- Hyaluronic acid facial fillers
- Skin quality treatments
- Facial contouring and rejuvenation
- Regenerative aesthetics
- Evidence-based aesthetic medicine
- Combination treatment protocols
Whether you already work with hybrid injectables or want to better understand how biostimulation fits into modern facial treatment planning, the webinar offers a focused look at both the science and clinical application behind this evolving area of aesthetic medicine.
Frequently Asked Questions
What is Genefill DX?
Genefill DX is a hybrid injectable combining hyaluronic acid and dextranomer, developed for facial aesthetic applications. Its formulation brings together structural correction with a biostimulatory component as part of a hybrid approach to facial aesthetics.
What is hybrid biostimulation?
Hybrid biostimulation refers to an aesthetic approach in which structural correction and biostimulatory activity are considered together within the treatment strategy.
What will the Genefill DX session cover?
Dr. Luis Mastronardi's session will focus on the clinical evidence behind Genefill DX and hybrid biostimulation, connecting the scientific principles of the formulation with its relevance in facial aesthetic practice.
Is Episode 3 only about Genefill DX?
No. Genefill DX is the focus of the facial clinical evidence session, while the wider webinar also covers skin quality, the science of hybrid biostimulation and advanced HYAcorp combination protocols for body contouring.
When is The Aesthetic EDGE Episode 3?
Hybrid Biostimulation: From Clinical Evidence to Combination Protocols for Face & Body takes place on Monday, 21 September 2026 at 15:00 UTC.
Explore the Clinical Evidence Behind Hybrid Biostimulation
Facial aesthetics is no longer only being defined by correction.
As treatment strategies continue to evolve, understanding how structural support, skin quality and biostimulatory approaches can work together is becoming increasingly relevant for aesthetic practitioners.
Join Genefill, BioScience and IMCAS Academy for Episode 3 of The Aesthetic EDGE to explore the science and clinical evidence behind hybrid biostimulation with Genefill DX — and discover how these principles fit into the wider evolution of facial and body aesthetic medicine.
